These observations indicate that VGLL3 induction contributes to the ESR1 repression and anti-tumour effect of Entinostat, thus revealing a potential mechanism of action for histone deacetylase inhibitor drugs in ER+ breast cancers. The gene discussed is VGLL3; the disease is breast cancer.